Simeox
Commercial- Indications
- Cystic fibrosis, Bronchiectasis, Chronic obstructive pulmonary disease
Company intelligence / Profile preview
PhysioAssist developed Simeox, an innovative CE-marked medical device for airway clearance that uses intermittent negative air pressure pulses to mobilize bronchial mucus. Clinical studies show high patient satisfaction and improved quality of life when used at home by patients with cystic fibrosis, bronchiectasis, or COPD. The company was acquired by Inogen in September 2023 to expand global reach and prepare for US commercialization. Ongoing clinical trials are evaluating long-term benefits versus standard of care.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PhysioAssist.